Hostname: page-component-75d7c8f48-bjh2l Total loading time: 0 Render date: 2026-03-13T19:55:41.999Z Has data issue: false hasContentIssue false
  • English
  • Français

Psychofarmacotherapy: history

Published online by Cambridge University Press:  18 September 2015

M.J.A.J.M. Hoes
Get access Rights & Permissions [Opens in a new window]

Summary

A survey of the history of psychopharmacotherapy is presented.

In Antiquity some psycho-active plant extracts were already known . Since the rise of chemistry in early nineteenth century, sedative drugs were synthesized first. Since the fifties of this century the four groups of psychotherapeutic drugs proper, anxiolytics, hypnotics, antipsychotics and antidepressants have been discovered.

Astute clinical or preclinical observation and the understanding of coincidences, serendipity, has been the basis of these discoveries. Since the prototypes were discovered, no real breakthroughs have been achieved.

Keywords

historypsychotropic drugsanxiolyticshypnoticsantipsychoticsantidepressantsgeschiedenispsychofarmacaanxiolyticahypnoticaantipsychoticaantidepressiva

Information

Type
Research Article
Information
Acta Neuropsychiatrica , Volume 6 , Issue 3 , September 1994 , pp. 48 - 58
Copyright
Copyright © Scandinavian College of Neuropsychopharmacology 1994

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

Literatuur

1.Burger, A. History. In: Usdin, E, Forrest, IS, red. Psychotherapeutic Drugs. New York: Dekker, 1976:11–59.Google Scholar
2.Caldwell, AE.History of psychopharmacology. In: Clark, WG, del Giudice, J, red. Principles of Psychopharmacology, sec ed. New York: Acad Press, 1978:9–41.Google Scholar
3.Prozac®: antidepressivum of kruid van Polydamna? Geneesmid-delenbulletin, Prikbord 1994;28(6):50–1.Google Scholar
4.MJAJM, Hoes. Historiografie-I. Soma & Psyche 1993;19(3):11–22.Google Scholar
5.MJAJM, Hoes. Van palmwijn tot Zolpidem. Papieren Visite 1993; 10(18):5–6.Google Scholar
6.Rudgley, R. The Alchemy of Culture. Intoxicants in Society. London: British Museum Press, 1993.Google Scholar
7.Bianchini, F, Coirbetta, F, Pistoia, M.De Plant in de Geneeskunde. Helmond: Helmond, 1976.Google Scholar
8.Lehane, B. The Power of Plants. Maidenhead: McGraw-Hill, 1977.Google Scholar
9.Bierman, AI.Theriak. Het mirakel triakel. Geschied Geneesk 1993;1:11–16.Google Scholar
10.Kuhn, R. Geschichte der medikamentösen Depressionsbehandlung. - von Opium zum Imipramin und seine Derivaten. In: Linde, OK, red. Pharmakopsychiatrie im Wandel der Zeit. Klingenmünster: Tilia, 1988:10–27.Google Scholar
11.Platter, F. Observationes.I. Bern: Huber, 1963.Google Scholar
12.Quincey, Th de.Bekentenissen van een Engelse opiumeter. Den Haag: Bakker, 1972.Google Scholar
13.Gabriel, RA, Metz, KS.A History of military Medicine. Vol. 1: From ancient Times to the Middle Ages. New York: Greenwood, 1992.Google Scholar
14.Pichois, C, red. Baudelaire, Ch.Du Vin et Du Hachish. Les Paridis artificiels. Paris: Livre de Poche, 1964: nr. 1326.Google Scholar
15.MJAJM, Hoes. 50 jaarLSD. Stand van zaken en perspectieven van hallucinogenen . TADP 1994:20: in druk.Google Scholar
16.MJAJM, Hoes. Cocaïne-afhankelijkheid: de neuropsychiatrische complicaties. In: De Smet, R, Treffers, PE, red. Bijblijven 10(2). Houten: Bohn Stafleu Van Loghum, 1994:33–40.Google Scholar
17.Heinrich, K. Psychopharmakologie seit 1952. Fortschr Neurol Psychiat 1994;62:31–40.CrossRefGoogle ScholarPubMed
18.Sternbach, L. Die Benzodiazepin-Story. In: Ibidem als 10:271–99.Google Scholar
19.Greenblatt, DJ.Clinical implications of pharmacokinetic differences among benzodiazepines. In: Hoes, MJAJM, Broers, M, Patay, M, red. Clinical Differentiation of Benzodiazepines. Maassluis: Sanofi, 1986:11–9.Google Scholar
20.Hoes, MJAJM. Antidepressiva: oude wijn in nieuwe zakken? Acta neuropsychiat 1989; 1(1): 8–13.Google Scholar
21.Klein, DF, Fink, M.Psychiatric reaction patterns to imipramine. Am J Psychiat 1962;119:432–8.CrossRefGoogle ScholarPubMed
22.Hoes, MJAJM, Colla, P, Folgering, H.Clomipramine treatment of hyperventilation syndrome. Pharmakopsychiat-Neuro-Psycho-pharmakol 1980;13:25–8.CrossRefGoogle ScholarPubMed
23.Hoes, MJAJM. De Paniekstoornis. In: Hoes, MJAJM. Praktische Psychiatric D1. 11. Arnhem: CIBA Nederland, 1991.Google Scholar
24.Hoes, MJAJM. L-tryptophaan in Depressie en Strain. Nijmegen: Academisch Proefschrift, 1981.Google Scholar
25.Boer, JA den. Serotonergic Mechanisms in Anxiety Disorders. An inquiry into serotonin function in panic disorder. Utrecht: Academisch Proefschrift, 1988.Google Scholar
26.Laborit, H. In: Ban, TA, Hippius, H, red. Psychopharmacology in Perspective. Heidelberg: Springer, 1988:63–7.Google Scholar
27.Delay, J, Deniker, P.Méthodes chimiothérapeutiques en Psychiatrie. Paris: Masson, 1961.Google Scholar
28.Nijdam, SJ.Ervaringen met moderne Psychofarmaca. Den Haag: Mouton, 1966.Google Scholar
29.Deniker, P. Nobel Prize and Albert Lasker Award. In: Ban, Th.A., Hippius, H, red. Towards CINP. From the Paris Colloquium through the Milan Symposium. Brentwood (TN): JM Prod, 1994.Google Scholar
30.Lassen, N. Die Geschichte der Thioxantenen. In: Ibidem als 10: 170–83.Google Scholar
31.Niemegeers, CJE. Paul Janssen und die Entdeckung von Haloperidol sowie anderer Neuroleptika. In: ibidem als 10:155–69.Google Scholar
32.Stille, Fischer-Cornelssen. Die Entwicklung von Clozapine (Leponex) - ein Mysterium? In: Ibidem als 10:333–48.Google Scholar
33.Meltzer, HY.Preface. In: Meltzer, HY, red. Novel antipsychotic Drugs. New York: Raven Press, 1992.Google Scholar
34.Justin-Besancon, L, Margarit, P, Hermann, J.Die Benzamiden - Entdeckung und Entwicklung in der Psychiatrie. In: Ibidem als 10: 349–71.Google Scholar
35.Friesewinkel, H. Die Zeit vom Reserpin zum Doxepin. In: Ibidem als 10:231–65Google Scholar
36.Lehmann, HE.Kline, N. In: ibidem als 22:26–9.Google Scholar
37.Butlan, Ibn. Das Aerztebankett (vert.: Klein-Franke F). Stuttgart: Hippokrates 1984.Google Scholar
38.Cohen Stuart, HM.Bezwaard Gemoed. Amsterdam: Academisch Proefschrift, 1960.Google Scholar
39.Loomer, HP, Saunders, IC, Kline, NS.A clinical and pharmacodynamic evaluation of iproniazid as psychic energizer. Psychiat Res Publ. APA 1957;8:129.Google ScholarPubMed
40.Pare, CMB. The present status of the monoamine oxidase inhibitors. Br J Psychiat 1985;146:576–84.CrossRefGoogle ScholarPubMed
41.Hoes, MJAJM. Remming van het monoamine oxidase (MAO): plaatsbepaling van moclobemide (Aurorix®). TGO/JDR 1993; 18:145–50.Google Scholar
42.Frey, R. Die Monoaminoxidase-Hemmer. In: Ibidem als 10:226–230.Google Scholar
43.Schou, M, Juel-Nielsen, N, StrSmgren, E, Voldby, H.The treatment of manic psychoses by the administration of lithiumsalts. J Neurol Neurosurg Psychiat 1954;17:250–60.CrossRefGoogle Scholar
44.Schou, M. Phasen in der Entwicklunsgeschichte des Lithiums als Psychopharmakon. In: Ibidem als 10:196–216.Google Scholar
45.Coppen, A. Depression as a lethal disease: prevention strategies. J clin Psychiat 1994;55 (4, suppl):37–45.Google ScholarPubMed
46.Hoes, MJAJM. Nieuw is zilver, oud is goud?! Over antidepressiva. TGO/JDR 1993;(1):17–23.Google Scholar
47.Song, F, Freemantle, N, Sheldon, TA, House, A, Watson, P, Long, A, Mason, J. Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. Br med J 1993;306:683–7.CrossRefGoogle ScholarPubMed
48.Sheldon, T, Mason, J, Song, F, Freemantle, N, House, A.Effective and acceptable treatment for depression. Br med J 1993;306:1124–7.CrossRefGoogle Scholar
49.Isacsson, G, Holmgren, P, Wasserman, D, Bergman, U.Use of antidepressants among people committing suicide in Sweden. Lancet 1994;308:506–9.Google ScholarPubMed
50.Bögels, GF.Katholieke koudwatervrees. In: ME van den, Peters-Ing, Renier, WO, Schoonderwaldt, HC, red. 40 Jaar Academische Neurologie in Nijmegen. Van zenuw- en zielsziekten tot een apart vak. Nijmegen: afd. Neurologie St. Radboud Ziekenhuis, 1994: 64–76.Google Scholar